Time to kick off my recap of the 2023-24 academic year! This week: Research papers I published, plus amicus briefs filed in my personal capacity (rather than on behalf of clinic clients). 1/

Exciting new vision for JACC Journals! I'm honored to work with Harlan Krumholz and the entire JACC Journals team.

The first issue under Harlan Krumholz, MD, FACC, showcases innovative, timely, & groundbreaking science, including a State-of-the-Art Review on the future of AI in cardiovascular care, a review of the history of CVD, & more. Read the full issue!

“The more that [drug companies] try to engage in this patent gaming strategy, the less they’re investing into actual research and development, and actually into novel innovation.” Dr. Ramachandran (Reshma Ramachandran) reminds of the opportunity costs associated with patent games.

7.4% of articles published in high-impact journals in 2022 were first posted as preprints, with no differences in Altmetric Scores or citations in articles with vs without preprints in the first years after publication. ja.ma/3LFOAPm @Hmkyale Joseph Ross Joshua D. Wallach

CRRIT’s Joshua D. Wallach, Reshma Ramachandran, & Joseph Ross new JAMA In Reply responds to comments on their article evaluating association strength between surrogate markers used as primary endpoints for trials supporting U.S. FDA approval of non-oncology drugs & clinical outcomes.

New study out in JAMA Network Open led by Yale Internal Medicine PGY-1 Maryam Mooghali, MD, MSc: U.S. FDA Breakthrough Therapy Designation has been remarkably effective at reducing late-stage R&D times, but are these drugs getting to market faster also clinically meaningful? 🤔healthaffairs.org/doi/abs/10.137… 1/

Quantitative bias analysis methods for summary level epidemiologic data in the peer-reviewed literature: a systematic review jclinepi.com/article/S0895-… via Joshua D. Wallach et al

Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments jamanetwork.com/journals/jama/… via Joseph Ross et al

We are recruiting! Join the exceptional faculty of Emory Public Health Dept of Health Policy & Management. Atlanta is the epicenter of #PublicHealth & Rollins is an exciting place to be. ~150 students in the dept ~$30M in associated research Join us! social.icims.com/viewjob/pt1725…

Come work with Holly Fernandez Lynch Naomi Scheinerman & I for a 2-yr funded postdoctoral fellow position in #AI and Health Policy Human Algorithm Collaboration Lab Emory University Winship Cancer Institute of Emory University! Working on #digitaltwins, in silico trials, FDA regulatory policy, & more. Apply or shoot me a DM if interested!

🔎 How do we balance rapid medical device innovation w/patient safety? Our recent Annals of Int Med paper, led by Kushal Kadakia, explores U.S. FDA’s latest reforms to 510(k) process, offering insights on future of med device regulation. Yale School of Medicine #MedTech #Regulation acpjournals.org/doi/10.7326/AN…

🎉 Celebrating 10 Years! 🎉 Amazing 10 yrs of Yale School of Medicine Yale School of Public Health YODA Project transforming clinical research sharing trials in partnership w/Johnson & Johnson! Together, we’ve strengthened science through transparency & data sharing 🌍📊. Joseph Ross #OpenScience yoda.yale.edu

New Research in JAMA: Looking through @CMSgov’s Coverage with Evidence Development (CED) program, Maryam Mooghali, MD, MSc, Sanket Dhruva, Joseph Ross, & Reshma Ramachandran examine whether CED studies are representative of Medicare beneficiaries across age, sex, and race/ethnicity. (1/5)

Preprints: A way to collaborate and garner feedback while advancing science – see the #JACC approach: jacc.org/doi/10.1016/j.… Harlan Krumholz Joshua D. Wallach

🚨 Big news from JACC! 🚨 Scientific publishing is evolving, and so are we. Our updated Preprint Servers Policy makes it easier than ever to include preprints in your submissions. Learn more from this #JACC Editor's Page 🔗 jacc.org/doi/10.1016/j.… Harlan Krumholz #CardioEd

Ever wondered if investigators requesting clinical trials data for secondary analyses actually follow the proposals they used to justify access to the data? The Yale Open Access group examine this question. Joshua D. Wallach Joseph Ross Harlan Krumholz SCTorg Open Access Data Centres

@YaleMedrecently highlighted the work of Yale NCSP alum Reshma Ramachandran, MD, MPP, MHS (Yale 2020–22) and how clinician-led research can reshape health policy and enable treatment access. tinyurl.com/yale-reshma Start your journey at NCSP! #NCSP #ApplyNow

🚨📢 Postdoc opening Emory Epidemiology in pharmaceutical regulation, evidence synthesis & meta-research. 1-year position w/ possible renewal. Formal posting coming soon—message or email me for details. Please share! Yale CRRIT METRICStanford Florian Naudet Research on Research Institute (RoRI) Joseph Ross